FDA accepts Merck biologics license application for allergy immunotherapy tablet
Data from five studies assessing the efficacy and safety profile of the tablet in adults with ragweed induced allergic rhinitis (with or without conjunctivitis) and 18 years of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.